Senetek and ICN partner for anaphylactic injector:
This article was originally published in Clinica
Senetek of Napa, California and ICN Pharmaceuticals of New York, have signed an agreement that gives ICN worldwide rights to AdrenaJect, Senetek's epinephrine filled ReliaJect autoinjector. The device is used by those suffering anaphylactic shock, caused by such events as adverse allergy reactions from insect bites or foods. Senetek will also make available the autoinjector for other therapeutics such as pains management and infertility.
You may also be interested in...
Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data.